Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Eitemau Tebyg

• Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
  gan: Pellagatti, A, et al.
  Cyhoeddwyd: (2006)
• Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
  gan: Pellagatti, A, et al.
  Cyhoeddwyd: (2007)
• Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
  gan: Jädersten, M, et al.
  Cyhoeddwyd: (2009)
• Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
  gan: Scharenberg, C, et al.
  Cyhoeddwyd: (2011)
• Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
  gan: Martin Jädersten, et al.
  Cyhoeddwyd: (2009-12-01)